SS
APRE icon

SBI Securities’s Aprea Therapeutics APRE Stock Holding History

SBI Securities’s Portfolio APRE Stock Details APRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13 Hold
16
– – ﹤0.01% 3898
2026
Q1 		$12 Buy
16
+1
+7% +$1 ﹤0.01% 3823
2025
Q4 		$13 Sell
15
-27
-64% -$33 ﹤0.01% 3840
2025
Q3 		$62 Buy
42
+2
+5% +$3 ﹤0.01% 3647
2025
Q2 		$68 Hold
40
– – ﹤0.01% 3648
2025
Q1 		$82 Hold
40
– – ﹤0.01% 3507
2024
Q4 		$132 Buy
+40
New +$134 ﹤0.01% 3379

Other funds holding APRE

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

SBI Securities's APRE Position: Q2 2026 in Review

SBI Securities held its Aprea Therapeutics (APRE) position steady in Q2 2026 at 16 shares worth $13. The position accounts for ﹤0.01% of the portfolio, ranked #3898.

SBI Securities first reported a position in APRE in Q4 2024 and has held it in 7 quarters since. The position peaked at $132 in Q4 2024. 28 funds tracked by Wall St. Rank hold APRE as of Q2 2026.

  • SBI Securities held 16 shares of Aprea Therapeutics worth $13 as of Q2 2026.
  • SBI Securities left its Aprea Therapeutics share count unchanged in Q2 2026.
  • Aprea Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #3898 holding.
  • SBI Securities first reported a position in Aprea Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • SBI Securities's Aprea Therapeutics position peaked at $132 in Q4 2024.
  • 28 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.